Etiology of the anemia/underlying disease | N | F/M | Median age | Age range |
Normal non-diabetic subjects | 36 | 19/17 | 54 | 31 - 73 |
Non-anemic diabetic patients | 18 | 9/9 | 59 | 43 - 74 |
Non-anemic control subjects in total | 54 | 28/26 | 57 | 31 - 74 |
Iron-deficiency anemia | 48 | 35/13 | 39 | 20 - 72 |
Megaloblastic anemia | 56 | 37/19 | 72 | 31 - 88 |
Anemia of chronic disease | 38 | 13/25 | 60 | 34 - 75 |
Hemolytic anemia | 24 | 10/14 | 55 | 25 - 78 |
β-thalassemic trait | 41 | 20/21 | 49 | 36 - 69 |
β-thalassemia major | 92 | 42/50 | 31 | 16 - 71 |
Sickle-cell/β-thalassemic trait | 23 | 10/13 | 33 | 18 - 56 |
Aplastic anemia | 20 | 9/ 11 | 42 | 23 - 74 |
Other anemias | 6 | 4/2 | 47 | 27 - 61 |
Non-MDS anemias in total | 348 | 180/168 | 48 | 16 - 88 |
MDS-refractory anemia | 102 | 33/69 | 71 | 41 - 87 |
MDS-RA with ringed side roblasts | 46 | 14/32 | 73 | 37 - 88 |
MDS-RA with excess of blasts | 92 | 19/73 | 68 | 45 - 87 |
MDS-RAEB in transformation | 13 | 5 / 8 | 70 | 58 - 87 |
MDS-CMML | 59 | 12/47 | 74 | 36 - 85 |
MDS-unclassified & hybrid MDS/MPN | 14 | 1 /13 | 75 | 64 - 83 |
MDS in total | 326 | 84/242 | 73 | 37 - 88 |
Polycythemia vera | 38 | 14/24 | 58 | 45 - 80 |
Essential thrombocythemia | 62 | 33/29 | 49 | 17 - 82 |
Myelofibrosis | 32 | 7/25 | 65 | 38 - 87 |
Ph+ chronic myelogenous leukemia | 18 | 3/15 | 47 | 29 - 78 |
Acute myelogenous leukemia | 23 | 6/17 | 64 | 31 - 81 |
Myeloproliferative syndromes in total | 173 | 63/110 | 56 | 17 - 87 |
Acute lymphoblastic leukemia | 2 | 1/1 | 42 | 18 - 67 |
Non Hodgkin’s lymphoma | 34 | 11/23 | 63 | 31 - 83 |
Hodgkin’s lymphoma | 8 | 2/6 | 36 | 29 - 72 |
Chronic lymphocytic leukemia | 30 | 15/15 | 68 | 40 - 79 |
Hairy-cell leukemia | 8 | 2/6 | 62 | 49 - 75 |
Plasma-cell dyscrasias | 78 | 39/39 | 66 | 38 - 84 |
Lymphoproliferative disorders in total | 161 | 70/91 | 65 | 18 - 84 |
Secondary erythrocytosis | 34 | 8/26 | 54 | 40 - 79 |
Total subjects tested | 1096 | 433/663 | 58 | 16 - 88 |